What's Happening

Consumer healthcare company Haleon, the maker of Advil, TUMS, and Biotène, is increasing U.S. sales by targeting people taking popular GLP-1 weight-loss drugs and addressing the gastrointestinal side effects those medicines can cause. (Reuters)

Through strategic retail partnerships, including with CVS Pharmacy, Haleon has positioned symptom-management products in dedicated weight-loss display sections alongside traditional store aisles, driving an average 24% sales increase per store. (Reuters)

The GLP-1 Consumer Base Is Growing

Widespread adoption of weight-loss therapies creates adjacent consumer health demand

With analytics firm Gallup reporting that roughly 11% of Americans currently use GLP-1 medications like Wegovy, Zepbound, and Foundayo, companies are successfully capturing secondary demand for symptom mitigation without competing directly in pharmaceuticals. (London South East)

What Side Effects Are Creating the Opportunity?

Gastrointestinal side effects spur demand for targeted over-the-counter remedies

Treatment initiation and dosage increases frequently trigger nausea, vomiting, constipation, diarrhea, and abdominal cramping, forming a distinct consumer health category focused on daily symptom management. (London South East)

Haleon's Product Portfolio Fits the New Demand

Repackaging existing brands around specific patient treatment journeys

Established everyday remedies like Advil for pain, TUMS for indigestion, and Biotène for oral care are being actively marketed directly within the context of GLP-1 therapy adjustments. (London South East)

The CVS Strategy

Dual-placement merchandising yields significant per-store sales lifts

Haleon's collaboration with CVS utilizes dual placement—keeping items in standard aisles while featuring them in dedicated GLP-1 displays—which generated a 24% sales boost in Q1 2026 and captured the majority of category shelf space. (London South East)

Why Dual Placement Matters

Capturing both intentional search and contextual treatment discovery

The merchandising approach successfully addresses multiple shopper behaviors by accommodating familiar product lookups while simultaneously educating consumers seeking targeted treatment support.

CVS Is Expanding the Category

Major retailers begin treating weight-loss drug users as a distinct consumer segment

CVS has actively broadened its product assortment, highlighting national and store-brand options designed specifically to alleviate GLP-1 side effects. (London South East)

Haleon Is Taking the Strategy to Other Retailers

Discussions with Walmart and Target signal potential nationwide retail shifts

While formal outcomes remain undisclosed, ongoing talks with other retail giants suggest that dedicated GLP-1 merchandising could soon become standard across the major U.S. market. (London South East)

A New Consumer-Health Ecosystem Around GLP-1 Drugs

Treatment-adjacent spending expands across nutrition, hydration, and care support

The massive surge in obesity drug adoption is catalysing a broader commercial ecosystem addressing evolving dietary habits, oral care, and ongoing wellness needs.

The Strategy Is About Consumer Context

Organizing retail environments around patient journeys rather than traditional categories

Re-contextualizing everyday remedies as active components of a therapeutic lifestyle transition transforms standard consumer touchpoints into specialized health solutions.

Why GLP-1 Users Are Valuable to Consumer-Health Companies

Long-term therapy creates sustained, recurring purchase opportunities

Because GLP-1 regimens typically span months or years, engaged consumer bases offer stable, long-term avenues for increasing basket sizes and cross-category sales.

The Rise of Treatment-Adjacent Spending

Commercial expansion reaches far beyond primary pharmaceutical manufacturers

From digital health platforms and specialized nutrition businesses to over-the-counter remedy providers, stakeholders across the healthcare landscape are tapping into adjacent market opportunities.

Why Retailers Are Paying Attention

Pharmacy analytics provide precise visibility into emerging consumer behaviors

Direct access to point-of-sale data allows retailers to optimize floor space, elevate the relevance of physical pharmacies, and capture growing non-prescription spend.

The Market Is Moving From Drugs to Patient Journeys

Shifting focus from prescriptions to holistic treatment experiences

Companies are learning to map their offerings across the entire patient arc—from initial dose titration to long-term maintenance and lifestyle adaptation.

Risks and Limitations

Responsible positioning remains vital to prevent overstatement of side-effect prevalence

Marketers must navigate carefully to ensure that promotional messaging respects individual patient variances and avoids implying that side effects are inevitable.

Why This Matters

Haleon's 2026 performance underscores how pharmaceutical booms can create highly lucrative derivative markets for consumer health companies capable of adapting their retail merchandising strategies. (London South East)

Looking Ahead

Tracking the expansion of dedicated retail health hubs and behavioral data

Future growth will depend on broader retail adoption, deeper cross-industry partnerships, and how effectively companies leverage real-time symptom and purchasing analytics.

Key Takeaways

  • Haleon is driving U.S. sales growth by targeting consumers using popular GLP-1 weight-loss medications. (Reuters)
  • Brand portfolio features staples like Advil, TUMS, and Biotène. (London South East)
  • Targeted side effects include nausea, vomiting, constipation, diarrhea, and abdominal cramping. (London South East)
  • Dual-placement displays at CVS yielded an average 24% per-store sales lift in Q1 2026. (London South East)
  • Haleon secured a commanding majority of GLP-1-related shelf space at CVS locations. (London South East)
  • Approximately 11% of Americans currently utilize GLP-1 weight-loss drugs. (London South East)
  • Exploratory merchandising discussions are underway with other major retailers like Walmart and Target. (London South East)
  • The strategy highlights a major shift toward marketing around holistic patient treatment journeys.

What This Means for Healthcare Marketers

Haleon's strategy is a strong example of marketing around a healthcare journey rather than marketing only around a product.

The company took existing brands and positioned them around a specific consumer context: people using GLP-1 medications and managing their side effects.

For healthcare marketers, the important signal is that a growing treatment population can create secondary demand across products, services and care experiences that were not originally designed specifically for that treatment.

The opportunity is to identify those adjacent needs through real behavioral data. Retail purchasing patterns, prescription growth, treatment adherence, symptom trends and patient journeys can reveal where new demand is emerging before a new product category is fully established.